Preliminary clinical data, including responses observed with revumenib and ziftomenib in early-phase trials (e.g., AUGMENT-101), support the extension of this therapeutic approach beyond KMT2A-rearranged and NPM1-mutated AML. The gene discussed is KMT2A; the disease is acute myeloid leukemia.